Li Ping Chung, Clinical Lead, WA Respiratory Health Network, Department of Health; Li.Chung@health.wa.gov.au
The Australasian Severe Asthma Dupilumab Registry (ASADR) is a treatment-specific registry attached to the larger Australasian Severe Asthma Registry (ASAR). The ASAR is a large registry which monitors the health and wellbeing of people in Australia and New Zealand who have uncontrolled or severe asthma. As dupilumab is now available on the PBS in Australia, the ASADR is an Australian module attached to ASAR. The purpose of the ASADR is to specifically monitor the health and wellbeing of people with asthma who are receiving dupilumab for the treatment of their severe asthma in Australia. The ASADR will be used to observe benefits and side effects of dupilumab, and to help researchers and clinicians better understand the use of dupilumab treatment in severe asthma. It will also contribute to the greater understanding of treatment options for the severe asthma population.
- Feedback to contributing clinicians
- Shared with other clinicians
- Shared with medical colleges
- Reported in Annual Report
- Asthma Control Questionnaire – 5 (ACQ-5)
- Asthma Quality of Life Questionnaire (AQLQ)
- Work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma)
- Global Rating of Change (GRoC)
Nil
New South Wales
- Campbelltown Hospital
- Concord Repatriation Hospital
- John Hunter Hospital Royal Newcastle Centre
- Liverpool Hospital
- Westmead Hospital
Queensland
- Mater Private Hospital (South Brisbane)
- Princess Alexandra Hospital
South Australia
- Royal Adelaide Hospital - Hampstead Rehabilitation Centre
Western Australia
- Fiona Stanley Hospital
Victoria
- Austin Health - Austin Hospital
- Box Hill Hospital
- The Alfred